Zimmer Biomet Holdings, Inc.
Analysis
Zimmer Biomet is deliberately trading growth for a rebuilt U.S. sales force: its 2026 revenue guidance opened at low single digits and has since been raised, with profit guidance lifted twice. That bet only pays if the new channel sells more per rep.How much of the 2026 raise came from the sales force versus new products?
- The U.S. sales-force rebuild is going better than management planned.
Most U.S. reps were non-dedicated and worked other jobs, so 2026 guidance opened at low single digits. Profit guidance has since been lifted twice - the transition is what decides whether growth lasts past 2027.
- Hips and technology are now carrying the company; knees are not.
U.S. hip growth hit 5.9% in Q2 FY2026 and U.S. technology sales grew over 50%. But global knee revenue was flat and international knees fell as China slumped, so the recovery rests on the smaller, faster businesses.What share of U.S. knee revenue is still in the brands being phased out?
- The rebuild is being paid for out of margin, and profit is not keeping up.
Q2 FY2026 adjusted EPS was flat even though revenue rose 4.8%, as operating margin fell over two points on distributor deals, 200 robotics reps and pay. Management says margin falls again this year, so profit arrives after the cost.How much of the 2026 margin decline is sales-force spend versus tariffs?
- Product cycle gaining tractionThe bull case is that the new product cycle is working, with hips, robotics and extremities growing faster than the market while the channel is rebuilt.
- Guidance raised during transitionManagement raised its full-year sales outlook after a strong first half, which supports the view that converting the sales force is costing less growth than planned.
- Cash generation funds buybacksFree cash flow grows every year and most of it goes back to shareholders through buybacks, so earnings per share can rise even when revenue growth is modest.
- Channel conversion drags growthThe bear case is that the sales force conversion runs through next year, so growth stays below the orthopedic market and the promised acceleration keeps slipping.
- Knee franchise losing shareKnees are the largest franchise and have stopped growing, which offsets faster growth in hips and robotics and leaves the company relying on smaller businesses.
- Margins falling with volumeSlower volume growth is pulling gross margin down, so profit per share depends more on cost cuts and buybacks than on the underlying business improving.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$1K | Jul 23 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 23 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 12 | Aug 22 |
Donald Trump Republican · Executive | Sale | ≥$15K | May 22 | Jul 1 |
Donald Trump Republican · Executive | Purchase | ≥$100K | May 11 | Jul 1 |
Congressional trading data provided by QuiverQuant
How Zimmer Biomet Holdings turned $8.2B of revenue into $1.1B of operating income.
| Revenue | ||
|---|---|---|
| Knees | $3.3B | ▲ 4.69% YoY |
| S E T | $2.2B | ▲ 15.25% YoY |
| Hips | $2.1B | ▲ 4.72% YoY |
| Total revenue | $8.2B | |
| Gross profit | $5.7B | 69.7% |
| Operating income | $1.1B | 13.3% |